High-throughput screening (HTS) of large chemical libraries has become the main source of new lead compounds for drug development. Several specialized detection technologies have been developed to facilitate the cost-and time-efficient screening of millions of compounds. However, concerns have been raised, claiming that different HTS technologies may produce different hits, thus limiting trust in the reliability of HTS data. This study was aimed to investigate the reliability of the authors most frequently used assay techniques: scintillation proximity assay (SPA) and homogeneous time-resolved fluorescence resonance energy transfer (TR-FRET). To investigate the data concordance between these 2 detection technologies, the authors screened a large subset of the Schering compound library consisting of 300,000 compounds for inhibitors of a nonreceptor tyrosine kinase. They chose to set up this study in realistic HTS scale to ensure statistical significance of the results. The findings clearly demonstrate that the choice of detection technology has no significant impact on hit finding, provided that assays are biochemically equivalent. Data concordance is up to 90%. The little differences in hit findings are caused by threshold setting but not by systematic differences between the technologies. The most significant difference between the compared techniques is that in the SPA format, more false-positive primary hits were obtained. (Journal of Biomolecular Screening 2006:606-616) 
INTRODUCTION
H IGH-THROUGHPUT SCREENING (HTS) has become one of the main sources for new chemical entities in the drug discovery field. Driven by advances in combinatorial chemistry and the resulting increase in size of the compound collections that are searched for new leads, productivity in HTS has grown strongly during the past decade, supported by many new assay formats and detection technologies as well as advances in laboratory automation. [1] [2] [3] Because typical HTS laboratories have nowadays the capabilities to screen up to a million compounds in a few weeks, the screening process itself no longer forms a bottleneck in drug discovery. Nonetheless, the huge increase in throughput has not led to a similar increase in output, that is, a sufficiently high number of novel chemical entities identified as development candidates. 4 One explanation for this is a high attrition rate of HTS hits due to pharmacokinetics and toxicologyrelated problems, a fact that is now addressed by placing ADMET studies earlier into the process. 5 Another important factor is the quality and lead likeness of the compound collection submitted to the screening process. 6, 7 On the other hand, there may be inherent problems of the HTS process itself, especially related to the use of specialized detection technologies that have been developed for the use in HTS. Nowadays, many different assay technologies available can be used for screening purposes. 8 To ensure high throughput, most of these technologies are proximity-based mix-and-measure techniques avoiding time-consuming separation steps. A drawback, however, is that the compounds that are screened for their action in a biochemical reaction are still present during the subsequent detection step, in which the reaction product is quantified. This leads to the well-known problem of compound interference. 8, 9 Compound interference can be easily handled by counterscreening the primary hits with an independent detection technology or by adding compounds to an already stopped biochemical reaction to sort out the artifacts. Although interfering compounds can be sorted out by such measures, there is a certain probability that real hits could be masked by such artifacts. This is especially important when pooling strategies are used to reduce costs and increase throughput because interference by one compound could mask a real effect of another one. Because different detection technologies may produce different artifacts, there may be a certain risk in missing different hits when using different detection technologies for HTS. This question has previously been addressed by others. [9] [10] [11] [12] [13] [14] Sills et al. 11 screened a randomly selected subset of 30,000 compounds for tyrosine kinase inhibitors with the alarming result that there was a very limited overlap of hits derived from the scintillation proximity assay (SPA), time-resolved fluorescence resonance energy transfer (TR-FRET), and fluorescence polarization (FP) assays and also that there was no significant correlation between IC 50 values obtained with SPA and the fluorescence-based techniques. A similarly alarming result was published by Wu et al. 12 for the nuclear receptor FXR. This study also clearly showed that screening in pools of 5 compounds led to a much higher number of false negatives than screening single compounds. Because we are using a screening strategy based on orthogonal pooling of 10 compounds per well, these reports alerted us to investigate the data concordance between the 2 detection technologies mostly used in our laboratory, which are SPA and TR-FRET. To gain a conclusive data set for the potential differences caused by the detection part of the assay, we performed the assays in the most similar way possible, aiming to have a biochemically equivalent enzymatic reaction, especially identical buffer, substrate, and substrate concentrations at their K m values. For this comparison, we used a tyrosine kinase assay that had been already used in the lab and screened the most recent addition of 300,000 compounds from the Schering compound library to ensure the highest possible compound quality. The number of 300,000 compounds tested is high enough to ensure highly significant results. To provide the best possible evaluation, we retested all hits from both assays in single with both technologies and performed IC 50 determinations in both technologies for all hits confirmed in both assays. By these means, we could base the analysis of false-positive and false-negative rates in primary screening on confirmed IC 50 hits.
The techniques SPA and TR-FRET are well established and known to be relatively robust against compound interference. For that reason, they are the routinely used detection techniques at Schering for kinase assays. The results of this study show that, using biochemically equivalent assays, the choice between SPA and TR-FRET has no significant impact on hit identification.
MATERIALS AND METHODS
An existing TR-FRET tyrosine kinase assay was adapted to a 5-µL assay volume, which recently has become the standard assay format for biochemical assays in our laboratory.
The TR-FRET procedure was performed in black, smallvolume 384-well plates (Greiner, Kremsmünster, Germany); SPA assays were performed in white, small-volume 384-well plates (Greiner). Assay buffer in both assay types contained 50 mM Tris/HCl (pH 7.4, Sigma-Aldrich T2663), 3 mM MnCl 2 (Sigma-Aldrich M1787), 0.1 mM Na 3 VO 4 , 2 mM DTT (Biomol #04010), 0.05% Tween-20 (Sigma-Aldrich P7949), Complete EDTA free (Roche Diagnostics, Alameda, CA), 0.01% bovine serum albumin (BSA, Sigma-Aldrich A7906), and 0.005% NP40 (Fluka 74385).
Library compounds in pools of 10 were used at a 1-mM concentration each in 100% DMSO. For screening, the HTS library was distributed into small-volume 384-well plates. Ready-to-use assay plates were prepared with 50 nL of compound solution per well. Assays were done in a 5-µL final volume, with a resulting compound concentration of 10 µM.
As neutral control, 50 nL 100% DMSO (Calbiochem #317275) was used, and 50 nL 100 µM staurosporine (Sigma-Aldrich S4400) in 100% DMSO served as inhibitor control. These controls were used to calculate Z´ values and signal-tobackground ratios during the HTS and to calculate the percent inhibition values for the screened compounds. For this normalization, the value of the neutral control was set to 0% inhibition; the value obtained for the inhibitor control was set to 100% inhibition. In addition, 50 nL 200 nM staurosporine was used as a standard for 50% inhibition (IC 50 staurosporine 2 nM) to monitor assay sensitivity during the screening.
TR-FRET tyrosine kinase assay
3-µL enzyme solution (25 pg/µL in assay buffer) was preincubated with 50-nL library compounds for 20 min at room temperature to allow for binding. 2-µL substrate solution containing peptide (0.75 µM) and adenosine triphosphate (ATP, 1.5 µM; Amersham Pharmacia #27-2056-01) was added, and the kinase reaction was then run for 20 min at room temperature (final concentrations: tyrosine kinase 0.15 nM [15 pg/µL], peptide 0.3 µM, ATP 0.6 µM). An n-terminally biotinylated 13-mer activation loop-derived peptide served as substrate for the assay.
Reactions were stopped by addition of a 2-µL stop buffer, which contained 70 mM EDTA (pH 8.0, Sigma-Aldrich E7889). For detection, 5 µL Europium-labeled antiphosphotyrosine antibody (PT66, PerkinElmer #AD0069) and APClabeled streptavidine (SA Xlent, CisBio #611SAXLB) in antibody buffer were added (final concentrations in the detection step: peptide 125 nM, PT66 0.5 nM, SA Xlent 31.25 nM). Due to the tetrameric structure of streptavidine, under these conditions, all peptide molecules can bind to SA Xlent, and the sensitivity range of the assay is only limited by the antiphosphotyrosine antibody to 1 nM phosphotyrosine in the detection step. To stay in that range, the linearity of the assay was checked (Fig. 1) . The linearity of the assay proves that detection reagents are not limiting but in excess over the product formed in the kinase reaction.
Antibody buffer for TR-FRET contained 50 mM HEPES (pH 7.0, Invitrogen 15630-056), 0.4% BSA (Sigma-Aldrich A7906), and 0.005% NP-40 (Fluka 74385). Plates were incubated overnight (4 °C) and TR-FRET signals measured the day after in a RUBYstar (BMG, Offenburg, Germany) plate reader. Excitation wavelength was 340 nm, and the emissions at 620 nm and 655 nm were measured with a 50-µsec delay time.
SPA tyrosine kinase assay
3-µL enzyme solution (167 pg/µL) was preincubated with 50 nL of compounds for 20 min at room temperature. 2-µL substrate solution containing peptide (0.75 µM) and ATP (1.5 µM; Amersham Pharmacia #27-2056-01, 0.01 µCi/µL ATP γ−33P, Easytides NEG/602H) was added (final concentrations: tyrosine kinase 1 nM [100 pg/µL], peptide 0.3 µM, ATP 0.6 µM, ATP 0.02 µCi/well) and incubated for 50 min at room temperature. The same n-terminally biotinylated 13-mer activation loop-derived peptide as used for the TR-FRET served as substrate for this assay.
Reactions were stopped by addition of a 15-µL stop buffer, which contained 30 mM EDTA (pH 8.0, Sigma-Aldrich E7889) and 1.66 mg/mL streptavidine-coated SPA beads (Amersham Biosciences #NIF1077) (final concentrations: beads 25 µg/well, EDTA 22.5 mM). The resulting concentration of biotin-binding sites on the SPA beads in the detection step was 0.125 µM; the concentration of peptide was 0.075 µM. Therefore, the sensitivity range of the assay was not limited by detection reagents. Nevertheless, the linearity of the assay was confirmed in a time course experiment ( Fig. 1) . Plates were sealed, incubated for 30 min at room temperature, centrifuged at 300g, and measured in a Topcount (PerkinElmer, Wellesley, MA) with a 1-min integration time.
Screening procedure
Both screens were performed under realistic conditions, as used routinely in lead discovery programs at Schering. Compounds were screened in pools of 10. Briefly, each compound is placed in 2 independent sets of 10 compounds by using an orthogonal matrix pooling strategy. In this approach, every compound is tested twice but in 2 different sets of pooled compounds. Active compounds are found after electronic deconvolution of the raw data. The pooling and deconvolution strategy has been published. 15 384-well ready-to-use assay plates were prepared by transferring 50-nL compound pools from mother plates with a HummingBird (Genomic Solutions, Ann Arbor, MI) (1 mM each in 100% DMSO). These ready-touse assay plates are currently being stored for up to 6 months at -20°C without loss of quality, as determined by reproducibility of IC 50 values (Bergsdorf et al., manuscript in preparation). 32 wells on the plate are left empty for later addition of controls.
For screening, assay plates were thawed and brought to room temperature (RT). 20 wells per plate were filled with 50 nL DMSO as neutral control and 6 wells with an IC 50 standard (50 nL 200 nM staurosporine), and 6 wells per plate were used for inhibitory controls (50 nL 100 µM staurosporine). All wells were then filled with 3 µL enzyme in assay buffer using a Multidrop Micro (ThermoLabsystems, Waltham, MA). After a 20-min preincubation at RT to ensure binding of slow-binding compounds to the kinase, 2-µL solution containing peptide substrate and ATP was added using a 384-well CybiWell pipettor (CyBio, Jena, Germany). The reaction was stopped by addition of EDTA and detection reagents. After incubation for developing detection signals, plates were read in a Topcount for SPA signals or a RUBYstar for TR-FRET signals.
After electronic deconvolution to identify active compounds using Schering's in-house HTS software, compounds that caused an average inhibition above 40%, with a difference between the data from 2 pools below 30%, were picked from the Schering REMP compound depository and submitted for retesting as single compounds. We submitted all hits to both assay types at this stage. The retest reactions were done independently in quadruplicate, and compounds with a median of inhibition above 50% were submitted for determination of IC 50 using inhibitor concentrations between 0.2 nM and 20 µM. Instead of performing a compound free-assay run with the later addition of compounds after stopping the biochemical reaction to identify assay interferences, as we do in routine HTS projects, interfering compounds were sorted out by submitting only hits that were confirmed in both assay types to the IC 50 determinations. This is equivalent to the strategy of performing a counterscreen with an independent assay technology.
RESULTS AND DISCUSSION

Assay development
For the analysis of effects caused by assay technologies (better described as detection technologies), it is mandatory to keep all other assay conditions (i.e., the biochemical parameters) as constant as possible. So the same assay buffer, as well as the identical activation loop-derived peptide substrate, was used for both assays, and both substrates were used at the same concentration in both assay types. The only difference was that 6.7-fold more enzyme had to be used to get sufficiently high signals with the SPA technique. However, in both cases, substrates were in large excess over the enzyme. We used the peptide substrate at its K m and then determined the apparent K m value for ATP under conditions of peptide at K m . The assay was then performed at K m app ATP conditions to ensure maximum sensitivity toward all kinds of inhibitors. 16 For the tyrosine kinase in this project, a biotinylated activation loop peptide was used as a substrate. Its K m value is 0.3 µM (data not shown). Using a 0.3-µM peptide, the apparent K m value for ATP was determined to be 0.6 µM (data not shown). These concentrations were then used for both HTS assays.
To ensure high sensitivity in hit finding, the enzymatic reaction has to be in the linear range. Figure 1 shows reaction kinetics at different enzyme concentrations. Based on these kinetics, 15 pg/µL kinase and a 20-min reaction time were used for the TR-FRET assay, whereas 100 pg/µL kinase with a 60-min reaction time was necessary to obtain a sufficiently high signal in the SPA assay. The superior sensitivity of the TR-FRET technology compared to the SPA technology has been observed in several projects at Schering, especially when the in-house kinase panel was recently shifted to the TR-FRET format as standard technique (Ulf Bömer, manuscript in preparation). The fact that both assays are in the linear range proves that the biochemical reactions are in the initial phase, and detection reagents are not limiting the sensitivity. Thus, both assays are biochemically equivalent, a fact that is reflected by the correlation of the staurosporine IC 50 (2 nM, data not shown) in both assays. Figure 2 demonstrates that, at the conditions chosen to perform the screening assays, there is also linearity with respect to the enzyme concentration used. The assay quality measured by Z´ factors 17 was above 0.7 in both assays. We consider the similar assay quality to be crucial for the following analysis because only similar data quality in both types of assays will exclude that differences in data scatter will be responsible for differences in hit identification.
Primary screening
In the screening campaigns, we tested 298,689 compounds in the pool 10 format. 15 One hundred seventy 384-well plates were screened in both assays. In our routine procedures, we include 20 wells with neutral controls and 6 wells containing inhibitor controls on every single assay plate, allowing for precise quality monitoring and data normalization to percentage of inhibition. Figure 3 displays the resulting Z´ values of all plates from these 2 HTS runs. The average Z´ value over the TR-FRET assay was 0.70; for the SPA assay, it was 0.74. Thus, assay quality was maintained at a very high level through both screening campaigns and therefore allows for systematic analysis of possible differences between the detection technologies. Only 2 assay plates in the TR-FRET screen had Z´ values below 0.4 and might have caused problems due to increased data scatter. However, an analysis of the false negatives in TR-FRET showed no correlation with these 2 plates.
In addition to the mere assay quality, the quality of an HTS campaign is also characterized by hit rates reflecting library character and quality as well as the sensitivity of the detection system to compound interferences. Figure 4 provides the histograms for the SPA and TR-FRET HTS runs. The TR-FRET histogram is slightly broader (standard deviation in the TR-FRET screen is 16% compared to a standard deviation of 14% in the SPA screen). On the other hand, the mean inhibition in the SPA assay is 8% compared to -1% mean inhibition in TR-FRET. These differences can be explained with the mode of interference that influences the different assay types. Interference with SPA assays is mainly caused by absorbance that gives positive values leading to the right-shifted histogram, whereas interference with TR-FRET is caused by fluorescent compounds that can increase or decrease the signal, depending on their spectral properties, which leads to histogram widening.
Recently, Wu et al. 9 published a comparison between TR-FRET and AlphaScreen, where they obtained strikingly broader histograms for the AlphaScreen format, indicating extremely high sensitivity to compound interference. This result that AlphaScreen is extremely sensitive toward compound interference is in agreement with observations at Schering. Among the fluorescence based-techniques, fluorescence intensity and fluorescence polarization are strongly affected by interferences. Compound interference caused by fluorescent compounds is strongly reduced by the ratiometric readout in TR-FRET, so we typically observe much less interference compared to fluorescence intensity or polarization assays. The compound interference that affects SPA is caused by absorbance (color quenching) and only leads to moderately increased hit rates (2-fold in this project) that are still tolerable. Thus, SPA and TR-FRET are the technologies suitable for screening pooled compounds due to their inherent robustness against compound interference. Figure 5 gives an overview of the results. A total of 298,689 compounds were screened. Using a hit criterion of 40% inhibition with a maximum difference of 30% between the 2 data points resulting from the self-deconvoluting orthogonal matrix, we obtained 743 primary hits in TR-FRET (hit rate 0.25%) and 1352 primary hits in the SPA assay (hit rate 0.44%). A total of 519 primary hits were found in both assays, indicating a very good correlation already at the pool 10 primary screening level. In the next step, all primary hits were retested in quadruplicate as single compounds. A median of inhibition above 50% was used as the hit criterion at this stage. As a result, we got 392 confirmed TR-FRET hits (hit rate 0.13%) and 388 confirmed SPA hits (hit rate 0.13%). The number of compounds that was confirmed in both assays, thus reflecting the "true hit rate" without assay artifacts, was 342. Already at this stage, it became clear that assay concordance in this study is very high, with 87% of the hits being cross-confirmed. Figure 6A demonstrates the excellent correlation between the 2 techniques. Hits are missed only due to threshold setting and data scatter but not for systematic reasons. For example, by using a lower confirmation criterion of 40% inhibition in the TR-FRET assay, even 370 of 388 SPA hits were confirmed in the TR-FRET format (95%). By applying the lower criterion of 40% in SPA, 375 of the 392 TR-FRET hits were confirmed (96%). We conclude that most hits that are missed when applying the same hit criterion are only missed due to threshold setting and the inevitable data scatter. An analysis of standard deviations derived from the quadruplicated retests showed that data scatter reaches a maximum in the region of 50% inhibition (data not shown). This is in agreement with the steep slope of inhibition curves in that range, which makes these samples more vulnerable to little changes in the effective inhibitor concentration.
Hit confirmation and data analysis
We then determined IC 50 values for all 342 cross-confirmed hits; 20 µM was the maximum compound concentration in the IC 50 analysis. We regard only compounds with an IC 50 value below 10 µM as a confirmed IC 50 hit because curve fitting is not precise close to the maximum test concentration. Again, we obtained a very good assay concordance: 259 IC 50 s below 10 µM were measured using the TR-FRET assay, and 271 IC 50 s below 10 µM were measured in the SPA format. There were 233 hits below 10 µM found in both assays, and thus there was a 90% overlap with the calculation based on TR-FRET IC 50 hits and an 86% overlap with the calculation based on SPA IC 50 hits. Assay concordance is reflected by the correlation between SPA-and TR-FRET-determined IC 50 values, as shown in Figure 6B . The r 2 value is over 0.8, which is in the range often observed for intra-assay correlation. 9 Even if the r 2 is calculated for all values close to and ≥ 20 µM, it is still high with 0.72. The linear correlation of IC 50 s with a slope of 1 shows that there is no systematic difference between the assays.
We also analyzed correlations based on an intra-assay-type and interassay-type mode ( Table 1) . For this, we used the quadruplicate data sets from the single retests of the 1576 primary hits. The intra-assay-type correlations for both assay types are excellent, with r 2 above 0.95. The fact that interassay-type correlations are slightly weaker than intra-assay correlations (r 2 values around 0.78) shows that little differences in data scatter may be caused by using different assay techniques. However, these differences are very moderate in our study, as seen by the high degree of cross-confirmation and overlap of IC 50 hits.
The most important parameter for judging the value of assay technologies in HTS is the false-negative rate. We based our analysis of the false-negative rate on the confirmed hits that gave an IC 50 ≤ 10 µM in both assays. By this, we focus our analysis on potent hits as we routinely do in lead discovery programs and also exclude any possible artifacts because these hits had been found in 2 independent techniques. We checked the primary pool-screening data in the TR-FRET and SPA format for these confirmed hits and calculated the false-negative rate based on a primary hit criterion of 40% inhibition, as used in the primary screening campaigns. Figure 7 shows that falsenegative rates are very low in this study: 10% false negatives in the TR-FRET mode and 2.5% in the SPA mode. This analysis also shows that an apparent difference in the false-negative rate is only seen for the whole set of IC 50 hits below the 10-µM IC 50 value. When the analysis is restricted to more potent hits with IC 50 s below 3 µM, no difference is seen anymore. When the primary screening data for the false negatives are analyzed in detail, it becomes clear that most false-negative hits originate from the data scatter or interference by other compounds but not from systematic differences. Figure 8 shows the primary screening data for the hits missed by applying the primary hit criterion of 40% inhibition. In the SPA format, we identified only 6 false negatives. All 6 false negatives were caused by data scatter or interference by other compounds present in the pool because for all 6, at least 1 of the 2 data points was above the hit criterion. In 4 cases, only 1 data point was below the threshold; in 2 cases, both were above threshold, but the compound was rejected because of the difference between the 2 values. Thus, all SPA false negatives were caused by data scatter or compound interference.
In the TR-FRET format, 17 compounds out of 24 false negatives had at least 1 data point above the hit criterion and were thus missed due to data scatter or compound interference only. Among these, 7 compounds even had a mean inhibition value above the hit criterion. Only 7 compounds were below the threshold in both data points. We conclude that most false negatives are caused by the combined action of data scatter and compound interference. Because every compound is mixed with 9 others in every pool, the data set associated with 1 compound contains the sum of 19 different influences. Taking this into account, the observed false-negative rate for TR-FRET with 10% can be considered to be low. However, the false-negative rate of SPA with 2.5% is much lower. The SPA format is affected by compound interference due to light absorption. This is the reason for a relatively high number of false-positive hits, as seen in this study, but avoids the generation of false negatives.
Due to the ratiometric readout, the TR-FRET format generates very few false positives. The higher number of false negatives in the TR-FRET mode is probably caused by compound interference because here light absorption of the 620-nm reference light will lead to higher ratios giving false negatives. False negatives could also be caused by compound fluorescence in the 655-nm range. The conclusion is that to maximize hit finding, pooled libraries should be screened with SPA than TR-FRET if the number of retests is not limited. This strategy avoids false negatives caused by compound interference. If there is a restriction in the number of retests that can be performed, TR-FRET is the technique of choice because it does not generate as many false positives as SPA does. In addition to these aspects, TR-FRET has other significant advantages, such as its high sensitivity, that strongly reduces enzyme consumption and costs.
Screening strategies
We think that high assay quality and robustness of SPA and TR-FRET against compound interference are the reasons why we find a very good overlap between hits obtained in different screening techniques. Wu et al. 9 recently showed that data scatter can be relatively high between several runs of the same assay. These authors reported an r 2 value between different AlphaScreen assays of only 0.59, whereas the correlation between TR-FRET runs was much better, with an r 2 value of 0.78. A main reason for identification of different hits in screening with different techniques 11, 12 may thus be the intra-assay-type variation in the AlphaScreen assay. Wu et al. also showed a much broader distribution of activities in AlphaScreen that hint toward compound interference as a reason for the increased data scatter.
The plethora of different detection technologies available is a challenge for every scientist involved in assay development and HTS. The choice of detection technology could seriously affect the outcome of the HTS campaigns. Thus, we strongly suggest carefully evaluating the suitability of the detection technologies for HTS under realistic screening conditions. Only then will the robustness against compound interference become evident. However, in the scientific literature and in information provided by commercial vendors, detection technologies are often described as high in quality and robust, without any hint of how they react to the presence of diverse chemicals in a realistic HTS run. The data presented herein show that, at least for 2 commonly used technologies, SPA and TR-FRET, the basic assumption of HTS-that an inhibitor will be found independently of the technology used-is valid under conditions of high assay quality and similar biochemical settings. Contrary findings 11, 12 are probably caused by differences in the assays that were specifically optimized for the detection technologies used and possibly by the fact that the AlphaScreen method, which was included in both studies, is especially sensitive toward compound interference. Other authors 13, 14 have also used constant biochemical settings, as done in this study, and also obtained very good correlations between different HTS techniques.
Although some drawbacks may be caused by pool screening, there is the advantage in the approach of self-deconvoluting matrices having 2 independent data points for each compound. Recently published studies using a test set of 25k compounds indicate that threshold setting and data scatter cause false negatives and false positives. The conclusion from these studies is that a self-deconvoluting matrix approach or a replicate analysis will strongly reduce false-negative rates. 18, 19 Data in this study confirm in large scale that generation of replicate data points may even outweigh the effect of increased compound interference in pool screening at least if robust detection technologies are chosen.
CONCLUSIONS
We performed this large-scale study to confirm the basic assumption in HTS that compounds that bind and inhibit an enzyme will be found independent of the detection technology used. Our results show that this basic assumption is valid for TR-FRET and SPA as detection technologies. Different assay technologies are giving the same hits if assays are performed under comparable biochemical settings. To ensure high-quality hit finding, we propose using assay conditions that ensure highest biochemical quality and sensitivity of the screening assay. If substrates are used at a concentration that equals their K m value, and the reaction time and the enzyme concentration are adjusted to stay within their linear ranges, inhibitors will be found independent of the detection technology chosen. There may be exceptions, such as when technologies are used that are extremely sensitive toward compound interference, but the results of this study demonstrate that both TR-FRET and SPA are robust technologies that give reliable results in HTS. We observed a slightly higher false-negative rate in TR-FRET, which is explained by the slightly higher sensitivity to compound interferences that increase the ratiometric readout and mask inhibitions. These effects become significant when working in pools of 10 compounds. A possible consequence would be to prefer the SPA technique for pool-screening approaches. On the other hand, one might consider a 10% false-negative rate tolerable if it allows one to avoid running radioactive assays, with their health and environmental issues, while 90% of all inhibitors are still identified.
